Top 200 OTC/HBC brands in 2006

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

The new approval is for a first-in-class TRPM8 receptor agonist to stimulate corneal sensory nerves to increase natural tear production.

The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.